CARLSBAD, Calif., Dec. 7, 2017 /PRNewswire/ -- Ionis
Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense
therapeutics, today announced that management will present a
company overview at the BMO Capital Markets 2017 Prescriptions for
Success Healthcare Conference on Thursday,
December 14, 2017 at 1:30 p.m.
ET in New York, NY.
A live webcast of the presentation will be available on the
"Investors & Media" section of the Ionis website. The replay
will be available within 48 hours and will be archived for a
limited time.
ABOUT IONIS PHARMACEUTICALS, INC.
Ionis is the leading
company in RNA-targeted drug discovery and development focused on
developing drugs for patients who have the highest unmet medical
needs, such as those patients with severe and rare diseases. Using
its proprietary antisense technology, Ionis has created a large
pipeline of first-in-class or best-in-class drugs, with over three
dozen drugs in development. SPINRAZA® (nusinersen)
has been approved in global markets for the treatment of
spinal muscular atrophy (SMA). Biogen is responsible for
commercializing SPINRAZA. Drugs that have successfully completed
Phase 3 studies include inotersen, an antisense drug Ionis is
developing to treat patients with hereditary TTR amyloidosis
(hATTR), and volanesorsen, an antisense drug discovered by Ionis
and co-developed by Ionis and Akcea Therapeutics to treat
patients with either familial chylomicronemia syndrome or familial
partial lipodystrophy. Akcea, an affiliate of Ionis, is a
biopharmaceutical company focused on developing and commercializing
drugs to treat patients with serious cardiometabolic diseases
caused by lipid disorders. If approved, volanesorsen will be
commercialized through Ionis' affiliate, Akcea. Inotersen filings
for marketing approval have been submitted in the U.S. and
EU. Volanesorsen filings for marketing approval have been
submitted in the U.S., EU, and Canada. Ionis' patents provide strong and
extensive protection for its drugs and technology. Additional
information about Ionis is available
at www.ionispharma.com.
IONIS' FORWARD-LOOKING STATEMENT
This press release
includes forward-looking statements regarding the therapeutic and
commercial potential of Ionis' technologies and products in
development, including SPINRAZA, inotersen and volanesorsen. Any
statement describing Ionis' goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, particularly those
inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around
such drugs. Ionis' forward-looking statements also involve
assumptions that, if they never materialize or prove correct, could
cause its results to differ materially from those expressed or
implied by such forward-looking statements. Although Ionis'
forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors
currently known by Ionis. As a result, you are cautioned not to
rely on these forward-looking statements. These and other risks
concerning Ionis' programs are described in additional detail in
Ionis' annual report on Form 10-K for the year ended December 31, 2016, and its most recent quarterly
report on Form 10-Q, which are on file with the SEC. Copies of
these and other documents are available from the Company.
In this press release, unless the context requires otherwise,
"Ionis," "Company," "we," "our," and "us" refers to Ionis
Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals,
Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals,
Inc. SPINRAZA® is a registered trademark of Biogen.
View original content with
multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-present-at-the-bmo-capital-markets-2017-prescriptions-for-success-healthcare-conference-300568040.html
SOURCE Ionis Pharmaceuticals, Inc.